Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SIRT6-IN-3 (compound 8a), a selective SIRT6 inhibitor (IC50 = 7.49 μM), impedes the proliferation of pancreatic ductal adenocarcinoma (PDAC) cells and prompts apoptosis. It enhances the responsiveness of cancer cells to gemcitabine by obstructing the DNA damage repair pathway, thus serving as a valuable tool in pancreatic cancer research [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | SIRT6-IN-3 (compound 8a), a selective SIRT6 inhibitor (IC50 = 7.49 μM), impedes the proliferation of pancreatic ductal adenocarcinoma (PDAC) cells and prompts apoptosis. It enhances the responsiveness of cancer cells to gemcitabine by obstructing the DNA damage repair pathway, thus serving as a valuable tool in pancreatic cancer research [1]. |
Targets&IC50 | SIRT1:80.52 μM, SIRT2:92.21 μM, SIRT6:7.46 μM, HDAC3:111.9 μM, HDAC6:96.77 μM, HDAC8:102 μM |
In vitro | SIRT6-IN-3 at a concentration of 25 μM induces a cell cycle arrest and apoptosis in PDAC cells after 48 hours of treatment [1]. When applied for 72 hours, SIRT6-IN-3 continues to hinder the proliferation of pancreatic cancer cells by inhibiting cellular signaling pathways [1]. |
In vivo | SIRT6-IN-3 exhibits antitumor effects in a murine tumor model [1]. When used in combination with gemcitabine (at a ratio of 2:1), SIRT6-IN-3 enhances the anticancer activity of gemcitabine [1]. |
Molecular Weight | 673.73 |
Formula | C21H30Br3ClN6S |
CAS No. | 3023471-40-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SIRT6-IN-3 3023471-40-8 Chromatin/Epigenetic DNA Damage/DNA Repair Sirtuin inhibitor inhibit